Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Consumer,Dupilumab,"Chronic rhinosinusitis with nasal polyposis (CRSwNP), maintenance treatment of uncontrolled disease",Dupilumab (DUPIXENT),Recommended for decline,,Respiratory System and Allergies
